83-2271-21　［受注停止］KRIBIOLISA Dirucotide （MBP8298） ELISA 1 x 96 wells　KBI5011

特徴

• Description：Immunoassay for quantitative estimation of Dirucotide in human serum, plasma and tissue extracts.
• Dirucotide （MBP8298） was developed by two research scientists （Dr.
• Kenneth G.
• Warren ＆ Ingrid Catz at the University of Alberta） for the treatment of Multiple Sclerosis （MS）.
• Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein （MBP）.
• The drug is exclusively licensed by BioMS Medical Corp., a Canadian-based biotechnology company.BioMS Medical received clearance from the Food ＆ Drug Administration （FDA） to initiate a phase III clinical trial, named MAESTRO-03, for secondary progressive MS patients in January 2007.
• An additional Phase III clinical trial for dirucotide, MAESTRO-01, is being undertaken in Canada and Europe.
• In September 2008, the drug was granted FDA fast-track for approval.
• On July 2009, a statement was released, stating "BioMS Medical Corp.
• today announced that Dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale （EDSS）, during the two-year MAESTRO- 01 Phase III trial in patients with secondary progressive multiple sclerosis （SPMS）.
• In addition, there were no statistically significant differences between Dirucotide and placebo on the secondary endpoints of the study", this means that the MAESTRO-02 and MAESTRO-03 trials are discontinued.
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The Dirucotide ELISA is a competitive immunoassay for the determination of Dirucotide.
• The antiserum is captured by antibodies coated on a 96-well plate.
• A constant concentration of Biotin Concentrate and varying concentrations of unlabeled standard or sample compete for binding specifically to the antiserum.
• Captured Bt-tracer is subsequently bound by SA-HRP （streptavidin-conjugated horseradish peroxidase）, which produces a soluble colored product after a substrate is added.
• The enzyme reaction is stopped by dispensing an acidic solution （H2SO4） into the wells after 10 min at room temperature turning the solution from blue to yellow.
• The optical density （OD） of the solution at 450 nm is inversely proportional to the amount of specific Dirucotide bound.